T1	DISO 16 35	reacciones adversas
#1	AnnotatorNotes T1	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T2	CHEM 68 78	paclitaxel
#2	AnnotatorNotes T2	C0144576; paclitaxel; Organic Chemical · Pharmacologic Substance
T3	CHEM 81 90	docetaxel
#3	AnnotatorNotes T3	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T4	CHEM 158 168	paclitaxel
#4	AnnotatorNotes T4	C0144576; paclitaxel; Organic Chemical · Pharmacologic Substance
T5	CHEM 171 180	docetaxel
#5	AnnotatorNotes T5	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T6	CHEM 282 292	paclitaxel
#6	AnnotatorNotes T6	C0144576; paclitaxel; Organic Chemical · Pharmacologic Substance
T7	CHEM 295 304	docetaxel
#7	AnnotatorNotes T7	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T8	CHEM 490 496	taxano
#8	AnnotatorNotes T8	C0796419; Taxanes; Organic Chemical
T9	PROC 617 643	suspensión del tratamiento
#9	AnnotatorNotes T9	C0850893; stop medication; Therapeutic or Preventive Procedure
T10	PROC 645 704	Se consultaron las historias clínicas y las órdenes médicas
T11	PROC 709 720	seguimiento
#10	AnnotatorNotes T11	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T12	PROC 815 834	estudio descriptivo
T13	PROC 883 894	seguimiento
#11	AnnotatorNotes T13	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T14	CHEM 1051 1061	paclitaxel
#12	AnnotatorNotes T14	C0144576; paclitaxel; Organic Chemical · Pharmacologic Substance
T15	CHEM 1064 1073	docetaxel
#13	AnnotatorNotes T15	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T16	CHEM 1234 1243	docetaxel
#14	AnnotatorNotes T16	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T17	PROC 1357 1368	tratamiento
#15	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	DISO 1450 1469	neoplasia de pulmón
#16	AnnotatorNotes T18	C0242379; Malignant neoplasm of lung; Neoplastic Process | C0684249; Carcinoma of lung; Neoplastic Process
T19	CHEM 1489 1498	docetaxel
#17	AnnotatorNotes T19	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T20	CHEM 1499 1509	cisplatino
#18	AnnotatorNotes T20	C0008838; cisplatin; Pharmacologic Substance · Inorganic Chemical
T21	CHEM 1533 1540	fármaco
#19	AnnotatorNotes T21	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T22	DISO 1572 1582	enfermedad
#20	AnnotatorNotes T22	C0012634; Disease; Disease or Syndrome
T23	CHEM 1655 1664	docetaxel
#21	AnnotatorNotes T23	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T24	CHEM 1671 1677	taxano
#22	AnnotatorNotes T24	C0796419; Taxanes; Organic Chemical
T25	DISO 1699 1721	problemas de seguridad
T26	PROC 56 64	infusión
#23	AnnotatorNotes T26	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T27	DISO 130 140	reacciones
#24	AnnotatorNotes T27	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T28	PROC 146 154	infusión
#25	AnnotatorNotes T28	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T29	PROC 241 260	Estudio de cohortes
#26	AnnotatorNotes T29	C0086027; Analysis, Cohort; Research Activity (?)
T30	PROC 268 278	infusiones
#27	AnnotatorNotes T30	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T31	PROC 414 422	infusión
#28	AnnotatorNotes T31	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T32	DISO 536 544	reacción
#29	AnnotatorNotes T32	C0559546; Adverse reactions; Pathologic Function
T33	PROC 556 564	infusión
#30	AnnotatorNotes T33	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T34	PROC 1167 1179	infusionales
#31	AnnotatorNotes T34	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T35	PROC 728 738	infusiones
#32	AnnotatorNotes T35	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T36	DISO 960 970	reacciones
#33	AnnotatorNotes T36	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T37	PROC 1037 1047	infusiones
#34	AnnotatorNotes T37	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T38	DISO 1156 1179	reacciones infusionales
T39	DISO 1431 1441	reacciones
#35	AnnotatorNotes T39	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T40	ANAT 1463 1469	pulmón
#36	AnnotatorNotes T40	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T41	PROC 1733 1741	infusión
#37	AnnotatorNotes T41	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T46	Date 354 367	julio de 2010
T47	Date 374 391	diciembre de 2011
T48	Duration 393 401	18 meses
T50	LIVB 461 469	paciente
#38	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T52	Spec_cue 597 599	si
T54	LIVB 770 780	enfermeras
#39	AnnotatorNotes T54	C0028661; Nurses; Professional or Occupational Group
T56	LIVB 1079 1088	pacientes
#40	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	Age 1104 1113	61,4 años
T58	LIVB 1131 1138	mujeres
#41	AnnotatorNotes T58	C0043210; Woman; Population Group
T59	LIVB 1198 1207	pacientes
#42	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	LIVB 1283 1292	pacientes
#43	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T64	LIVB 252 260	cohortes
#44	AnnotatorNotes T64	C0599755; Cohort; Population Group
A1	Assertion T9 Speculated
T42	Quantifier_or_Qualifier 1586 1594	avanzada
A2	Assertion T42 Negated
T43	Neg_cue 1583 1585	no
R1	Negation Arg1:T43 Arg2:T42	
R2	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T42	
R3	Causes Arg1:T26 Arg2:T1	
R4	Used_for Arg1:T2 Arg2:T26	
R5	Used_for Arg1:T3 Arg2:T26	
R6	Causes Arg1:T28 Arg2:T27	
R7	Used_for Arg1:T4 Arg2:T28	
R8	Used_for Arg1:T5 Arg2:T28	
R9	Experiences Arg1:T64 Arg2:T30	
R10	Used_for Arg1:T6 Arg2:T30	
R11	Used_for Arg1:T7 Arg2:T30	
R12	After Arg1:T29 Arg2:T46	
R13	Before Arg1:T29 Arg2:T47	
R14	Has_Duration_or_Interval Arg1:T29 Arg2:T48	
T44	CONC 442 456	datos clínicos
#45	AnnotatorNotes T44	C1516606; Clinical Data; Intellectual Product
R15	Experiences Arg1:T50 Arg2:T31	
R16	Used_for Arg1:T8 Arg2:T31	
R17	Experiences Arg1:T50 Arg2:T8	
R18	Causes Arg1:T33 Arg2:T32	
R19	Speculation Arg1:T52 Arg2:T9	
R20	Before Arg1:T33 Arg2:T9	
R21	Before Arg1:T32 Arg2:T9	
T45	CONC 664 682	historias clínicas
#46	AnnotatorNotes T45	C0945958; Clinical notes and chart sections; Intellectual Product | C5204342; Clinical History; Intellectual Product
R24	Used_for Arg1:T14 Arg2:T37	
R25	Used_for Arg1:T15 Arg2:T37	
R26	Experiences Arg1:T56 Arg2:T37	
R27	Has_Age Arg1:T56 Arg2:T57	
R28	Has_Age Arg1:T58 Arg2:T57	
R29	Experiences Arg1:T58 Arg2:T37	
R30	Causes Arg1:T34 Arg2:T38	
#47	AnnotatorNotes T38	C2368034; Infusion reaction; Pathologic Function
R31	Experiences Arg1:T59 Arg2:T38	
R32	Experiences Arg1:T59 Arg2:T34	
R33	Causes Arg1:T16 Arg2:T38	
R34	Experiences Arg1:T59 Arg2:T16	
R35	Experiences Arg1:T60 Arg2:T16	
T49	Quantifier_or_Qualifier 1331 1353	primer o segundo ciclo
R36	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T49	
R37	Overlap Arg1:T38 Arg2:T17	
R38	Experiences Arg1:T60 Arg2:T17	
R39	Experiences Arg1:T60 Arg2:T38	
R40	Causes Arg1:T17 Arg2:T38	
R41	Used_for Arg1:T16 Arg2:T17	
R42	Used_for Arg1:T16 Arg2:T34	
R43	Location_of Arg1:T40 Arg2:T18	
R44	Overlap Arg1:T39 Arg2:T18	
R45	Causes Arg1:T19 Arg2:T39	
R46	Combined_with Arg1:T19 Arg2:T20	
R48	Causes Arg1:T21 Arg2:T39	
T51	Quantifier_or_Qualifier 1541 1557	en primera línea
R49	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T51	
R50	Overlap Arg1:T39 Arg2:T22	
R51	Causes Arg1:T23 Arg2:T25	
R52	Causes Arg1:T24 Arg2:T25	
R53	Causes Arg1:T41 Arg2:T25	
R54	Used_for Arg1:T24 Arg2:T41	
R55	Used_for Arg1:T23 Arg2:T41	
T53	Spec_cue 188 196	posibles
T55	CONC 197 203	causas
A3	Assertion T55 Speculated
#48	AnnotatorNotes T55	C1314792; Etiology; Functional Concept
R56	Speculation Arg1:T53 Arg2:T55	
T61	Spec_cue 927 932	podía
T62	CONC 933 940	influir
A4	Assertion T62 Speculated
#49	AnnotatorNotes T62	C0521102; Interferes with; Functional Concept
R57	Speculation Arg1:T61 Arg2:T62	
#50	AnnotatorNotes T42	C0205179; Advanced phase; Qualitative Concept
#51	AnnotatorNotes T25	C2362502; Safety Issues; Injury or Poisoning
A5	Experiencer T64 Patient
A6	Experiencer T50 Patient
A7	Experiencer T54 Other
A8	Experiencer T56 Patient
A9	Experiencer T58 Patient
A10	Experiencer T59 Patient
A11	Experiencer T60 Patient
